SCCA | Strategic Alliance Partners

Latest from SCCA


Expanding Armamentarium Underscores the Importance of Close Monitoring in Urothelial Cancer

October 12, 2021

With new therapeutic options, such as enfortumab vedotin-ejfv and, available to treat patients with locally advanced or metastatic urothelial cancer who require second- or third-line therapy, early detection of disease progression is critical.

Maintenance Therapy, Adjuvant and Escalated Approaches Garner Excitement in GU Cancers

October 11, 2021

Efforts to move beyond chemotherapy alone for patients with advanced urothelial cancer, shift effective treatments into the curative setting in renal cell carcinoma, and effectively escalate treatment for patients with high-risk and high-volume prostate cancer have been successfully met.